↓ Skip to main content

Dabigatran: Review of Pharmacology and Management of Bleeding Complications of This Novel Oral Anticoagulant

Overview of attention for article published in Journal of Medical Toxicology, September 2011
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

blogs
1 blog
twitter
2 tweeters
facebook
3 Facebook pages

Citations

dimensions_citation
80 Dimensions

Readers on

mendeley
118 Mendeley
Title
Dabigatran: Review of Pharmacology and Management of Bleeding Complications of This Novel Oral Anticoagulant
Published in
Journal of Medical Toxicology, September 2011
DOI 10.1007/s13181-011-0178-y
Pubmed ID
Authors

Michael Ganetsky, Kavita M. Babu, Steven D. Salhanick, Robert S. Brown, Edward W. Boyer

Abstract

Dabigatran (Pradaxa) is a competitive direct thrombin inhibitor approved by the US FDA for prevention of embolic stroke in patients with nonvalvular atrial fibrillation. Dabigatran has a pharmacokinetic profile that produces predictable anticoagulation responses, does not undergo CYP 450 metabolism, has few drug-drug and drug-food interactions, and does not require frequent laboratory monitoring of clotting parameters. Clinicians are rapidly prescribing this agent as a replacement for warfarin therapy. However, no therapeutic agent has been accepted to reliably reverse the hemorrhagic complications of dabigatran. As of yet, there is no solid evidence to guide management of bleeding complications; management should start with local control of bleeding when possible and transfusion of pRBCs if needed. Transfusion of FFP would not be expected to help control bleeding. Limited and mixed data exist for transfusion of factor VIIa and prothrombin complex concentrates; these therapies should be considered as well as dialysis, which will increase elimination in patients with life-threatening or closed-space bleeding due to dabigatran. We present an article that reviews the pharmacokinetics, clinical trial literature, and consensus guidelines regarding this novel oral anticoagulant.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 118 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
Chile 1 <1%
Slovenia 1 <1%
South Africa 1 <1%
Brazil 1 <1%
United States 1 <1%
Colombia 1 <1%
Unknown 111 94%

Demographic breakdown

Readers by professional status Count As %
Student > Master 26 22%
Researcher 17 14%
Student > Bachelor 15 13%
Other 14 12%
Professor > Associate Professor 9 8%
Other 37 31%
Readers by discipline Count As %
Medicine and Dentistry 78 66%
Pharmacology, Toxicology and Pharmaceutical Science 15 13%
Unspecified 11 9%
Agricultural and Biological Sciences 7 6%
Biochemistry, Genetics and Molecular Biology 4 3%
Other 3 3%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 June 2019.
All research outputs
#1,144,281
of 13,183,153 outputs
Outputs from Journal of Medical Toxicology
#112
of 453 outputs
Outputs of similar age
#8,307
of 91,986 outputs
Outputs of similar age from Journal of Medical Toxicology
#5
of 10 outputs
Altmetric has tracked 13,183,153 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 453 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.7. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 91,986 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.